share_log

海翔药业(002099.SZ)：目前公司CMO/CDMO业务战略客户存量业务保持良好的增长势头

Haixiang Pharmaceutical (002099.SZ): Currently, the company's CMO/CDMO business strategic customer stock business maintains a good growth momentum

Gelonghui Finance ·  May 20 21:38

Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Form shows that the company set up a new major customer department, and the chairman personally led the team to connect with potential customers to dig deeper into strategic customer project cooperation. At the same time, it quickly responds to customer needs with the company's own advantages such as quality system, process optimization ability, and commercial large-scale production capacity, and provides strong support for customer project registration and certification, and achieve rapid commercial implementation of the project. Currently, the company's CMO/CDMO business has maintained a good growth momentum, and new strategic customer projects are continuing to be implemented. Projects cooperating with European and American original research and pharmaceutical companies are in the verification stage, and commercialization will begin one after another after customers complete registration changes. The Class 1.1 innovative drug CDMO project, which added the original pharmaceutical company, has entered the implementation stage, and is expected to become the company's first Class 1 sterile innovative drug CDMO project. The featured platform's supporting products have successfully entered the original research industry chain and achieved a small amount of commercial supply.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment